Comparative therapeutic effects of velaglucerase Alfa and imiglucerase in a gaucher disease mouse model

PLoS ONE

Volumn 5, Issue 5, 2010, Pages

  Xu, You Hai ^a,b   Sun, Ying ^a,b   Barnes, Sonya ^a   Grabowski, Gregory A ^a,b  

^a CINCINNATI CHILDREN S HOSPITAL RESEARCH FOUNDATION   (United States)

^b UNIVERSITY OF CINCINNATI   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSYLCERAMIDASE; GLUCOSYLCERAMIDE; IMIGLUCERASE; IMMUNOGLOBULIN E; RECOMBINANT ENZYME; UNCLASSIFIED DRUG; VELAGLUCERASE ALFA;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTIBODY RESPONSE; ARTICLE; CELL COUNT; CHO CELL; CONTROLLED STUDY; DISEASE MODEL; DOSE RESPONSE; DRUG ABSORPTION; DRUG DOSE COMPARISON; DRUG EFFECT; DRUG MECHANISM; DRUG STABILITY; DRUG UPTAKE; ENZYME ACTIVE SITE; ENZYME ACTIVITY; GAUCHER DISEASE; HUMAN; HYPERSENSITIVITY; IN VITRO STUDY; IN VIVO STUDY; LIPID LIVER LEVEL; LIPID STORAGE; MOUSE; NONHUMAN; PH; PHARMACODYNAMICS; SARCOMA CELL; THERMOSTABILITY; TREATMENT DURATION;

ANIMALS; ANTIBODY FORMATION; CATALYTIC DOMAIN; DISEASE MODELS, ANIMAL; ENZYME INHIBITORS; ENZYME STABILITY; GAUCHER DISEASE; GLUCOSYLCERAMIDASE; HUMANS; HYDROGEN-ION CONCENTRATION; INHIBITORY CONCENTRATION 50; INJECTIONS, INTRAVENOUS; MICE; ORGAN SPECIFICITY; PEPTIDE HYDROLASES; SAPOSINS;

MUS;

EID: 77956289133     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0010750     Document Type: Article

References (50)

1. Beutler E, Grabowski GA (2001) Gaucher Disease. In: Scriver CR, Beaudet AL, Sly WS, Valle D, eds. The Metabolic and Molecular Basis of Inherited Disease. New York: McGraw-Hill. pp 3635-3668.
2. Lee RE (1982) The pathology of Gaucher disease. Prog Clin Biol Res 95: 177-217.
3. Deduve C (1964) From Cytases to Lysosomes. Fed Proc 23: 1045-1049.
4. Fratantoni JC, Hall CW, Neufeld EF (1968) Hurler and Hunter syndromes: mutual correction of the defect in cultured fibroblasts. Science 162: 570-572.
5. Barton NW, Brady RO, Dambrosia JM, Di Bisceglie AM, Doppelt SH, et al. (1991) Replacement therapy for inherited enzyme deficiency-macrophagetargeted glucocerebrosidase for Gaucher's disease. N Engl J Med 324: 1464-1470.
6. Grabowski GA, Barton NW, Pastores G, Dambrosia JM, Banerjee TK, et al. (1995) Enzyme therapy in type 1 Gaucher disease: comparative efficacy of mannose-terminated glucocerebrosidase from natural and recombinant sources. Ann Intern Med 122: 33-39.
7. Zimran A, Elstein D, Levy-Lahad E, Zevin S, Hadas-Halpern I, et al. (1995) Replacement therapy with imiglucerase for type 1 Gaucher's disease. Lancet 345: 1479-1480.
8. Weinreb NJ, Charrow J, Andersson HC, Kaplan P, Kolodny EH, et al. (2002) Effectiveness of enzyme replacement therapy in 1028 patients with type 1 Gaucher disease after 2 to 5 years of treatment: a report from the Gaucher Registry. Am J Med 113: 112-119.
9. Friedman B, Vaddi K, Preston C, Mahon E, Cataldo JR, et al. (1999) A comparison of the pharmacological properties of carbohydrate remodeled recombinant and placental-derived beta-glucocerebrosidase: implications for clinical efficacy in treatment of Gaucher disease. Blood 93: 2807-2816.
10. Pastores GM, Sibille AR, Grabowski GA (1993) Enzyme therapy in Gaucher disease type 1: dosage efficacy and adverse effects in 33 patients treated for 6 to 24 months. Blood 82: 408-416.
11. Rosenthal DI, Doppelt SH, Mankin HJ, Dambrosia JM, Xavier RJ, et al. (1995) Enzyme replacement therapy for Gaucher disease: skeletal responses to macrophage-targeted glucocerebrosidase. Pediatrics 96: 629-637.
12. Wenstrup RJ, Bailey L, Grabowski GA, Moskovitz J, Oestreich AE, et al. (2004) Gaucher disease: alendronate disodium improves bone mineral density in adults receiving enzyme therapy. Blood 104: 1253-1257.
13. Charrow J, Dulisse B, Grabowski GA, Weinreb NJ (2007) The effect of enzyme replacement therapy on bone crisis and bone pain in patients with type 1 Gaucher disease. Clin Genet 71: 205-211.
14. Kaplan P, Mazur A, Manor O, Charrow J, Esplin J, et al. (1996) Acceleration of retarded growth in children with Gaucher disease after treatment with alglucerase. J Pediatr 129: 149-153.
15. Fallet S, Grace ME, Sibille A, Mendelson DS, Shapiro RS, et al. (1992) Enzyme augmentation in moderate to life-threatening Gaucher disease. Pediatr Res 31: 496-502.
16. Beutler E, Kay A, Saven A, Garver P, Thurston D, et al. (1991) Enzyme replacement therapy for Gaucher disease. Blood 78: 1183-1189.
17. Kacher Y, Brumshtein B, Boldin-Adamsky S, Toker L, Shainskaya A, et al. (2008) Acid beta-glucosidase: insights from structural analysis and relevance to Gaucher disease therapy. Biol Chem 389: 1361-1369.
18. Grabowski GA, Kacena K, Cole JA, Hollak CE, Zhang L, et al. (2009) Doseresponse relationships for enzyme replacement therapy with imiglucerase/ alglucerase in patients with Gaucher disease type 1. Genet Med 11: 92-100.
19. Charrow J, Andersson HC, Kaplan P, Kolodny EH, Mistry P, et al. (2004) Enzyme replacement therapy and monitoring for children with type 1 Gaucher disease: consensus recommendations. J Pediatr 144: 112-120.
20. Sato Y, Beutler E (1993) Binding, internalization, and degradation of mannoseterminated glucocerebrosidase by macrophages. J Clin Invest 91: 1909-1917.
21. Furbish FS, Steer CJ, Krett NL, Barranger JA (1981) Uptake and distribution of placental glucocerebrosidase in rat hepatic cells and effects of sequential deglycosylation. Biochim Biophys Acta 673: 425-434.
22. Bijsterbosch MK, Donker W, van de Bilt H, van Weely S, van Berkel TJ, et al. (1996) Quantitative analysis of the targeting of mannose-terminal glucocerebrosidase. Predominant uptake by liver endothelial cells. Eur J Biochem 237: 344-349.
23. Xu YH, Ponce E, Sun Y, Leonova T, Bove K, et al. (1996) Turnover and distribution of intravenously administered mannose-terminated human acid beta-glucosidase in murine and human tissues. Pediatr Res 39: 313-322.
24. Bove KE, Daugherty C, Grabowski GA (1995) Pathological findings in Gaucher disease type 2 patients following enzyme therapy. Hum Pathol 26: 1040-1045.
25. Pastores GM, Weinreb NJ, Aerts H, Andria G, Cox TM, et al. (2004) Therapeutic goals in the treatment of Gaucher disease. Semin Hematol 41: 4-14.
26. Chaney W, Stanley P (1986) Lec1A Chinese hamster ovary cell mutants appear to arise from a structural alteration in N-acetylglucosaminyltransferase I. J Biol Chem 261: 10551-10557.
27. Elbein AD, Tropea JE, Mitchell M, Kaushal GP (1990) Kifunensine, a potent inhibitor of the glycoprotein processing mannosidase I. J Biol Chem 265: 15599-15605.
28. Grace ME, Newman KM, Scheinker V, Berg-Fussman A, Grabowski GA (1994) Analysis of human acid beta-glucosidase by site-directed mutagenesis and heterologous expression. J Biol Chem 269: 2283-2291.
29. Liou B, Kazimierczuk A, Zhang M, Scott CR, Hegde RS, et al. (2006) Analyses of variant acid beta-glucosidases: effects of Gaucher disease mutations. J Biol Chem 281: 4242-4253.
30. Brooks DA, Kakavanos R, Hopwood JJ (2003) Significance of immune response to enzyme-replacement therapy for patients with a lysosomal storage disorder. Trends Mol Med 9: 450-453.
31. Burrow TA, Hopkin RJ, Leslie ND, Tinkle BT, Grabowski GA (2007) Enzyme reconstitution/replacement therapy for lysosomal storage diseases. Curr Opin Pediatr 19: 628-635.
32. Rosenberg M, Kingma W, Fitzpatrick MA, Richards SM (1999) Immunosurveillance of alglucerase enzyme therapy for Gaucher patients: induction of humoral tolerance in seroconverted patients after repeat administration. Blood 93: 2081-2088.
33. Xu YH, Quinn B, Witte D, Grabowski GA (2003) Viable mouse models of acid beta-glucosidase deficiency: the defect in Gaucher disease. Am J Pathol 163: 2093-2101.
34. Brumshtein B, Greenblatt HM, Butters TD, Shaaltiel Y, Aviezer D, et al. (2007) Crystal structures of complexes of N-butyl- and N-nonyl-deoxynojirimycin bound to acid beta-glucosidase: insights into the mechanism of chemical chaperone action in Gaucher disease. J Biol Chem 282: 29052-29058.
35. Lieberman RL, Wustman BA, Huertas P, Powe AC, Jr., Pine CW, et al. (2007) Structure of acid beta-glucosidase with pharmacological chaperone provides insight into Gaucher disease. Nat Chem Biol 3: 101-107.
36. Premkumar L, Sawkar AR, Boldin-Adamsky S, Toker L, Silman I, et al. (2005) X-ray structure of human acid-beta-glucosidase covalently bound to conduritol- B-epoxide. Implications for Gaucher disease. J Biol Chem 280: 23815-23819.
37. Sluiter W, Oomens LW, Brand A, Van Furth R (1984) Determination of blood volume in the mouse with 51chromium-labelled erythrocytes. J Immunol Methods 73: 221-225.
38. Parwaresch MR, Radzun HJ, Kreipe H, Hansmann ML, Barth J (1986) Monocyte/macrophage-reactive monoclonal antibody Ki-M6 recognizes an intracytoplasmic antigen. Am J Pathol 125: 141-151.
39. Tsuji S, Choudary PV, Martin BM, Winfield S, Barranger JA, et al. (1986) Nucleotide sequence of cDNA containing the complete coding sequence for human lysosomal glucocerebrosidase. J Biol Chem 261: 50-53.
40. Qi X, Leonova T, Grabowski GA (1994) Functional human saposins expressed in Escherichia coli. Evidence for binding and activation properties of saposins C with acid beta-glucosidase. J Biol Chem 269: 16746-16753.
41. Fabbro D, Desnick RJ, Grabowski GA (1987) Gaucher disease: genetic heterogeneity within and among the subtypes detected by immunoblotting. Am J Hum Genet 40: 15-31.
42. Bergmann JE, Grabowski GA (1989) Posttranslational processing of human lysosomal acid beta-glucosidase: a continuum of defects in Gaucher disease type 1 and type 2 fibroblasts. Am J Hum Genet 44: 741-750.
43. Brumshtein B, Salinas P, Peterson B, Chan V, Silman I, et al. (2010) Characterization of gene-activated human acid-{beta}-glucosidase: Crystal structure, glycan composition, and internalization into macrophages. Glycobiology 20: 24-32.
44. Van Patten SM, Hughes H, Huff MR, Piepenhagen PA, Waire J, et al. (2007) Effect of mannose chain length on targeting of glucocerebrosidase for enzyme replacement therapy of Gaucher disease. Glycobiology 17: 467-478.
45. Du H, Levine M, Ganesa C, Witte DP, Cole ES, et al. (2005) The role of mannosylated enzyme and the mannose receptor in enzyme replacement therapy. Am J Hum Genet 77: 1061-1074.
46. Hollak CE, de Fost M, van Dussen L, Vom Dahl S, Aerts JM (2009) Enzyme therapy for the treatment of type 1 Gaucher disease: clinical outcomes and dose - response relationships. Expert Opin Pharmacother 10: 2641-2652.
47. McEachern KA, Fung J, Komarnitsky S, Siegel CS, Chuang WL, et al. (2007) A specific and potent inhibitor of glucosylceramide synthase for substrate inhibition therapy of Gaucher disease. Mol Genet Metab 91: 259-267.
48. Dinur T, Osiecki KM, Legler G, Gatt S, Desnick RJ, et al. (1986) Human acid beta-glucosidase: isolation and amino acid sequence of a peptide containing the catalytic site. Proc Natl Acad Sci U S A 83: 1660-1664.
49. Sun Y, Quinn B, Witte DP, Grabowski GA (2005) Gaucher disease mouse models: point mutations at the acid beta-glucosidase locus combined with low-level prosaposin expression lead to disease variants. J Lipid Res 46: 2102-2113.
50. Olszewski MA, Huffnagle GB, McDonald RA, Lindell DM, Moore BB, et al. (2000) The role of macrophage inflammatory protein-1 alpha/CCL3 in regulation of T cell-mediated immunity to Cryptococcus neoformans infection. J Immunol 165: 6429-6436.